Research Specialties (Reported growth: Q3: 13.6%, YTD: 13.0%; Organic growth: Q3: 8.8%, YTD: 8.6%): This unit continued its strong performance in Q3 2007, enabling it to exceed its 6% long-term organic growth target for the fifth successive quarter. Stronger academic demand in the U.S. continued for the second successive quarter. Improved marketing efforts, such as coordinating the capabilities of Research Essentials and Research Specialties to leverage our customer centric approach and the addition of new tools to drive Internet promotions and interactions, helped sales growth in all key geographic regions. Better product availability from intentional inventory increases and new supplier relationships in CAPLA markets continued to fuel double-digit organic growth for Research Specialties in these markets as well.
Research Biotech (Reported growth: Q3: 11.2%, YTD: 7.0%; Organic growth: Q3: 7.2%, YTD: 3.4%): Improved sales growth during the third quarter from that realized over the first six months of 2007 reflected stronger spending by academic customers, results from our addition of more sales specialists and the expansion of our product offerings through internal development efforts and technology licenses. Molecular biology product sales were particularly strong. Consistent pricing for synthetic DNA products in more recent quarters helped stabilize sales of these products for the third quarter.
SAFC (Fine Chemicals; Reported growth: Q3: 19.8%. YTD: 20.0%; Organic
growth: Q3: 6.1%, YTD: 8.5%): After achieving record sales of $153.2
million in Q2 2007, sales in Q3 2007 remained very strong at $149.0
million. Results benefited f
Copyright©2007 PR Newswire.
All rights reserved